Trial reportJournal of molecular neuroscience : MN2026
Clinical Study on the Combined Use of Tadalafil and Epalrestat in the Treatment of Diabetic Neurovascular Erectile Dysfunction.
Trial report in Journal of molecular neuroscience : MN, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study aims to evaluate the clinical efficacy of tadalafil combined with epalrestat in the treatment of diabetic neurovascular erectile dysfunction (ED). Eighty patients diagnosed with diabetic neurovascular ED admitted to between January 2022 and October 2024 were randomly allocated into two groups (n = 40 each). The control group received tadalafil monotherapy, while the observation group was additionally treated with epalrestat. Both regimens lasted 12 weeks. Outcomes assessed pre- and post-treatment included International Index of Erectile Function-5 (IIEF-5), Erection Hardness Score (EHS), modified Sexual Life Quality Questionnaire (mSLQQ-QoL), penile hemodynamic parameters [peak systolic velocity (PSV), end-diastolic velocity (EDV), resistance index (RI)], and serum markers of endothelial function [endothelin-1 (ET-1), von Willebrand factor (vWF), and asymmetric dimethylarginine (ADMA)]. Treatment safety was also evaluated. Post-treatment, both groups showed significant improvements in IIEF-5 scores, proportion of EHS grade III-IV, and mSLQQ-QoL scores, with greater changes observed in the combination group (P < 0.05). The combination group also demonstrated higher PSV and RI, and lower EDV, ET-1, vWF, and ADMA levels than the control group (P < 0.05). No drug-related adverse events occurred in either group (P > 0.05). Tadalafil combined with epalrestat therapy for diabetic neurovascular ED can synergistically improve erectile function, erection hardness, sexual life quality, penile hemodynamics, and vascular endothelial function, with good safety and no increased risk of drug-related adverse events.
Indexed as
Identifiers
41961401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.